A Case Report of Pulmonary Exacerbation after Initiation of Lumacaftor/Ivacaftor Therapy in a CF Female with Complicated Lung Disease
Novel targeted treatments for Cystic Fibrosis give rise to new hope for an ever-growing number of CF patients with various mutations. However, very little evidence and guidelines exist to steer clinical decisions regarding patients whose illness takes an unexpected course. In such cases, the benefit...
Saved in:
Main Authors: | Elpis Hatziagorou, Eleana Kouroukli, Vasiliki Georgopoulou, John Tsanakas |
---|---|
Format: | Article |
Language: | English |
Published: |
Wiley
2018-01-01
|
Series: | Case Reports in Pulmonology |
Online Access: | http://dx.doi.org/10.1155/2018/8394370 |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Does Pseudomonas aeruginosa Colonization Affect Exercise Capacity in CF?
by: Asterios Kampouras, et al.
Published: (2019-01-01) -
Body composition changes and clinical outcomes in pediatric cystic fibrosis during 24 months of lumacaftor ivacaftor therapy based on real-world data
by: Marcell Imrei, et al.
Published: (2025-01-01) -
Impact of elexacaftor/tezacaftor/ivacaftor (ETI) on the prescription refill rate (PRR) for inhaled medications in people with CF: an Italian multicenter analysis
by: Andrea Gramegna, et al.
Published: (2025-01-01) -
Preservation of cfRNA in cytological supernatants for cfDNA & cfRNA double detection in non‐small cell lung cancer patients
by: Yidan Ma, et al.
Published: (2024-09-01) -
Exacerbation of Pulmonary Fibrosis Following Single Lung Transplantation
by: Dawei Yang, et al.
Published: (2012-01-01)